Key Highlights

● The filing states conditions give rise to substantial doubt about continuing as a going concern.

● Cash was US$31,944 at 30 June 2026, down from US$681,480 at year-end.

● The working capital deficit was US$5,282,776 and the six-month net loss US$2,500,418.

● ABVC plans to distribute about 15% of BioKey Cayman shares to shareholders.

ABVC BioPharma, Inc. (NASDAQ:ABVC) is a Nevada corporation based in Fremont, California, and its common stock, par value US$0.001, trades on Nasdaq under the symbol ABVC. The cover page shows 26,654,365 shares outstanding as of 10 August 2026.

The company is a smaller reporting company. Its filing states that conditions give rise to substantial doubt about whether it can continue as a going concern, and management's plan relies on improving operations, raising capital and seeking support from related parties.

Results and liquidity

The company reported no revenue for the six months ended 30 June 2026. The net loss for the quarter was US$810,481, and for the six months it was US$2,500,418, of which US$2,297,176 was attributable to ABVC shareholders. A third-party summary says the loss compares with US$2,332,833 for the second quarter of 2025 and US$3,277,023 for the first half of 2025.

Cash and cash equivalents were only US$31,944 at 30 June 2026, down from US$681,480 at the end of 2025, and restricted cash fell from US$645,505 to nil. Short-term investments were US$62,420. Current assets of US$411,729 compare with current liabilities of US$5,694,505, producing a working capital deficit of US$5,282,776. Operating cash outflow for the half-year was US$1,138,656.

Funding and balance sheet

Net cash from financing was negative US$115,972 for the six months, as private offerings of US$319,492 and warrant exercises of US$102,000 were more than offset by other outflows. Total assets were US$19,400,715, total liabilities US$7,131,155 and total equity US$12,269,560. Much of the asset base is therefore not cash, which matters because the going-concern language concerns liquidity. At the first-half rate of cash use, the remaining cash would cover only a very short period, which is the arithmetic behind the cautionary language and the reliance on further financing.

One asset-related item is that title to land at Puli was transferred to Yun Zhi Yi on 20 July 2026, after the period end.

Corporate actions and licensing

BioKey Cayman, a subsidiary, had its Form 10 declared effective on 25 June 2026. ABVC plans to distribute about 4,500,000 BioKey Cayman shares, roughly 15%, to its shareholders pro rata, retaining about 85%. The distribution was first scheduled for 3 August 2026, was postponed.

The filing also describes November 2023 licences to AiBtl, under which each licensee, ABVC and BioLite Taiwan, pays US$3.5 million plus royalties of 5% of net sales up to US$100 million, for central nervous system products aimed at major depressive disorder and ADHD.

A Thin Cash Balance and Reliance on External Financing

ABVC shows a pattern common among small-cap biotechnology companies: modest spending, no product revenue and a balance sheet that depends on external financing and asset or licence monetisation. Any new equity raising could dilute existing holders, though the filing does not state that one is planned.